Efficacy, Safety, and Biomarker Analysis of 5 Mg and 7.5 Mg Doses of Crizanlizumab in Patients with Sickle Cell Disease: Primary Analyses from the Phase III STAND Study

被引：11
|
作者：
Abboud, Miguel R. [1 ]
Cancado, Rodolfo D. [2 ]
De Montalembert, Mariane [3 ]
Smith, Wally R. [4 ]
Rimawi, Hala [5 ]
Voskaridou, Ersi [6 ]
Guvenc, Birol [7 ]
Keefe, Deborah [8 ]
Grosch, Kai [9 ]
Nassin, Michele L. [8 ]
Watson, Jimmy [10 ]
Yssel, Justin [10 ]
Reshetnyak, Evgeniya [8 ]
Adomakoh, Yvonne Dei [11 ]
机构：
[1] Amer Univ Beirut, Dept Pediat & Adolescent Med, Med Ctr, Beirut, Lebanon
[2] Hosp Samaritano Sao Paulo, Dept Hematol Oncol, Sao Paulo, Brazil
[3] Necker Enfants Malades Hosp, AP HP, Dept Gen Pediat & Pediat Infect Dis, Paris, France
[4] Virginia Commonwealth Univ, Div Gen Internal Med, Dept Med, Richmond, VA USA
[5] Jordan Univ Sci & Technol, Fac Med, Irbid, Jordan
[6] Laikon Gen Hosp, Thalassaemia Ctr, Athens, Greece
[7] Cukurova Univ, Fac Med, Dept Hematol, Adana, Turkiye
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Novartis Pharma AG, Basel, Switzerland
[10] Novartis Ireland Ltd, Global Hlth DU, Dublin, Ireland
[11] Univ Ghana, Med Sch, Korle Bu Teaching Hosp, Accra, Ghana
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-185429
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Efficacy and Safety of 24 Weeks of Therapy with Bendroflumethiazide 1.25 mg/day or 2.5 mg/day and Potassium Chloride Compared with Enalapril 10 mg/day and Amlodipine 5 mg/day in Patients with Mild to Moderate Primary HypertensionA Multicentre, Randomised, Open Study
    S. Rasmussen
    N. Borrild
    J. Vang Andersen
    Clinical Drug Investigation, 2006, 26 : 91 - 101
  • [42] Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma
    Nakaigawa, Noboru
    Tomita, Yoshihiko
    Tamada, Satoshi
    Tatsugami, Katsunori
    Osawa, Takahiro
    Oya, Mototsugu
    Kanayama, Hiroomi
    Miura, Yuji
    Sassa, Naoto
    Nishimura, Kazuo
    Nozawa, Masahiro
    Masumori, Naoya
    Miyoshi, Yasuhide
    Kuroda, Shingo
    Kimura, Akiko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (03) : 416 - 426
  • [43] Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma
    Noboru Nakaigawa
    Yoshihiko Tomita
    Satoshi Tamada
    Katsunori Tatsugami
    Takahiro Osawa
    Mototsugu Oya
    Hiroomi Kanayama
    Yuji Miura
    Naoto Sassa
    Kazuo Nishimura
    Masahiro Nozawa
    Naoya Masumori
    Yasuhide Miyoshi
    Shingo Kuroda
    Akiko Kimura
    International Journal of Clinical Oncology, 2023, 28 : 416 - 426
  • [44] DEGARELIX VERSUS LEUPROLIDE DEPOT (7.5 MG): RESULTS FROM A 12-MONTH, RANDOMIZED, OPEN-LABEL, PHASE III STUDY IN PATIENTS WITH PROSTATE CANCER
    Persson, B. E.
    Boccon-Gibod, L.
    Klotz, L.
    Schroder, F. H.
    Andreou, C.
    Cantor, P.
    Jensen, J. K.
    Olesen, T. K.
    RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S318 - S318
  • [45] Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (Results from the EXPLORER study)
    Ballantyne, Christie M.
    Weiss, Robert
    Moccetti, Tiziano
    Vogt, Anja
    Eber, Bernd
    Sosef, Froukje
    Duffield, Emma
    AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (05): : 673 - 680
  • [46] SAFETY AND EFFICACY OF EVEROLIMUS GIVEN AT 10 MG/DAY IN ADVANCED RENAL CELL CARCINOMA (RCC) PATIENTS WITH STAGE III TO V CHRONIC KIDNEY DISEASE (CKD)
    Cosmai, Laura
    Porta, Camillo
    Foramitti, Marina
    Masini, Cristina
    Sabbatini, Roberto
    Malberti, Fabio
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 157 - 157
  • [47] Primary efficacy and safety results from the AMALEE trial evaluating 600 mg vs 400 mg starting doses of first-line ribociclib in patients with HR+/HER2-advanced breast cancer
    Cardoso, Fatima
    Jacot, William
    Kuemmel, Sherko
    Gupta, Sudeep
    Balaraman, Rama
    Lebedeva, Liudmila
    Ji, Yan
    Lakshmanan, Aparna
    Amin, Khalid
    Li, Zheng
    Sparano, Joseph
    CANCER RESEARCH, 2023, 83 (05)
  • [48] Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study
    Cho, Byoung Chul
    Obermannova, Radka
    Bearz, Alessandra
    McKeage, Mark
    Kim, Dong-Wang
    Batra, Ullas
    Borra, Gloria
    Orlov, Sergey
    Kim, Sang-We
    Geater, Sarayut L.
    Postmus, Pieter E.
    Laurie, Scott A.
    Park, Keunchil
    Yang, Cheng-Ta
    Ardizzoni, Andrea
    Bettini, Anna C.
    de Castro, Gilberto, Jr.
    Kiertsman, Flavia
    Chen, Zhe
    Lau, Yvonne Y.
    Viraswami-Appanna, Kalyanee
    Passos, Vanessa Q.
    Dziadziuszko, Rafal
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (07) : 1255 - 1265
  • [49] Efficacy and safety of 5 mg olanzapine for the prevention of carboplatin-induced nausea and vomiting in patients with thoracic malignancies: A prospective multicenter phase II study
    Fujita, Y.
    Iihara, H.
    Shimokawa, M.
    Sakai, C.
    Ikemura, S.
    Hirose, C.
    Kotake, M.
    Funaguchi, N.
    Gomyo, T.
    Imai, H.
    Hakamata, J.
    Kaito, D.
    Minato, K.
    Arai, T.
    Kawazoe, H.
    Suzuki, A.
    Ohno, Y.
    Okura, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S1175 - S1176
  • [50] Comparative Efficacy and Safety Profile of Amlodipine 5 mg/Losartan 50 mg Fixed-Dose Combination and Amlodipine 10 mg Monotherapy in Hypertensive Patients Who Respond Poorly to Amlodipine 5 mg Monotherapy: An 8-Week, Multicenter, Randomized, Double-Blind Phase III Noninferiority Study (vol 33, pg 1953, 2011)
    Kang, S. M.
    CLINICAL THERAPEUTICS, 2012, 34 (08) : 1844 - 1844
12345